Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
An early human trial seeks answers.
Two new gene-editing therapies may offer a functional cure, but cost and access issues could limit their use.
The first three people who received the experimental therapy experienced no serious adverse effects or toxicities.
Experimental gene therapy excises HIV-like virus from infected cells in monkeys.
Gene therapy that alters CCR5 receptors and excises HIV from infected cells eliminated the virus in mice.
EBT-101 is novel gene-editing therapy that uses “molecular scissors” to cut HIV out of cells.
One new approach protects CD4 cells against HIV entry, while another snips out viral genes in infected cells.
The National Institutes of Health awarded grants for HIV cure research to these 10 organizations. One focuses on pediatric populations.
An experimental approach to protect HIV-fighting T cells has been cleared for its first human trial.
Trying to mimic the “Berlin Patient” cure, researchers edited the CCR5 gene in the immune stem cells of a man with leukemia and HIV.
The researcher used CRISPR/Cas9 technology to render a pair of twins resistant to HIV.
This finding from early laboratory research may aid in the quest for cure therapies.
CRISPR gene editing eliminates HIV in mice
This amfAR grant hopes to find out. It’s part of $1.16 million in new funding from ARCHE.
A third of mice treated with gene editing technique plus long-acting antiretrovirals showed no remaining traces of HIV.
A look at HIV-related headlines across the globe
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.